Victrelis boceprevir: Phase III data
A pre-specified analysis of 912 patients with chronic HCV genotype 1 infection enrolled in 1 of 3 Phase III trials showed that interleukin-28B (IL-28B; IFNL3) genotype status (C/C, C/T or T/T) was a strong predictor of viral response in patients receiving Victrelis. Specifically, in patients carrying the C/C gene allele (n=28%), 89% of treatment-naïve and 82% of treatment-failure patients had an early virologic response defined as undetectable HCV RNA levels at week 8. In patients carrying the C/T (n=54%) or T/T (n=18%), 52% of treatment-naïve and 48% of treatment-failure patients had an early virologic response. The trial enrolled patients who received at least 1 dose of Victrelis or standard therapy and consented to genomic analysis to test for IL-28B polymorphisms. Data were presented at the European Association for the Study of the Liver meeting in Berlin. ...